Q-omics provides the consensus-scored RNF123 profile across patient tissues and cancer cell-line models. RNF123 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RNF123 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RNF123 RNA expression shows 20,569 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where RNF123 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF123 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF123 survival associations across molecular data types. RNF123 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF123 RNA expression–survival associations across cancer types. High RNF123 expression shows unfavorable associations in ACC and LUSC, but favorable associations in UVM, KIRC, KIRP and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for RNF123 RNA expression.
This table summarizes RNF123 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF123. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF123 shows lower tumor expression in KIRC, LUSC and KICH and higher tumor expression in LIHC, COAD and STAD. The KIRC box plot shows higher RNF123 RNA expression in normal versus tumor tissue (log2 FC = −0.754, t-test p < 0.001).
This table shows molecular features associated with RNF123 in patient tissues and cancer cell lines. In patient samples, RNF123 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF123 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
